Hytera Offers Communications Support in Indonesia’s Lombok Earthquake
A magnitude-6.9 earthquake hit the Indonesian islands of Lombok and Bali at around 6.45pm on August 5th, 2018, with more than 90 people dead and hundreds more injured. The immediate focus is search, rescue and meeting the basic needs of people affected by the earthquake. To improve collaboration efficiency in the search, rescue and evacuation, Hytera donated communications devices in the first minute to Palang Merah Indonesia (PMI), the Indonesian Red Cross, and also has stayed connecting with the Blue Sky Rescue and International Federation of Red Cross and Red Crescent Societies to stand by per the nation’s request for international rescue efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180809005363/en/
PMI members were binding a wound of an earthquake survivor (Photo: Business Wire)
In the morning of August 6, Hytera Indonesian subsidiary in Jakarta set up a 7-member emergency response team and immediately contacted PMI, as its volunteers and staff have been providing medical support to the survivors and also helped to evacuate people from the coastal areas. After confirming PMI was in need of mobile communications support, Hytera local team soon came out with a mission critical communications solution, consisting of advanced digital two-way radios, mobile radio and repeater.
On August 7, Tuesday morning, a joint meeting between Hytera engineers and PMI technicians was organized to go through the solution details and possible scenarios where the solution could be used for. At 3pm on August 7, Hytera communications devices were handed over to the PMI team, and its emergency response team were standby to provide assistance for upcoming rescue efforts.
“About one week ago I saw Basarnas (Indonesia Emergency Rescue Department) was using your devices in the last Lombok Earthquake. I am familiar with your brand. When you proposed to donate equipment, I am so excited. I hope that those devices could be used into the rescue as soon as possible. Thank you for your help,” said Mr. Sunarbowo Sandi, Head of the PMI Headquarter, when receiving devices from Jerry Gao, Sales Manager ASEAN of Overseas Sales Department at Hytera.
At the same time, Hytera headquarters CSR team in Shenzhen, China, contacted the Blue Sky Rescue and the East Asia of International Federation of Red Cross and Red Crescent Societies to offer necessary help once needed.
Gwendolyn Pang, Head of East Asia, International Federation of Red Cross and Red Crescent Societies, said, “I was informed that yesterday that Mr. David Yang, a Hytera Regional Marketing Manager from Shenzhen, delivered 50 handsets, 1 mobile radio and 1 repeater to the Indonesian Red Cross office in Jakarta. The International Federation of Red Cross and Red Crescent Societies (IFRC) and Indonesian Red Cross welcome more donations for the earthquake operation. IFRC would like to establish a regional or global partnership with Hytera. Together, let’s make the world safer!” Hytera will continue to pay attention to the disaster and provide communications support to help reconstruction in the first moment.
Hytera, a leading global provider of innovative Professional Mobile Radio (PMR) communications solutions, is committed to fulfilling its social responsibilities by leveraging cutting-edge technology and product portfolio to support rescue and relief operations on a global scale. Hytera played an active role in providing support to emergency response efforts such as the Japan Tsunami in 2011, the Nepal Earthquake in 2015, the floods in Myanmar in 2016, Hurricane Harvey in Houston, Texas in 2017 and Laos Dam Collapse in last month.
About PT. Hytera Communications Indonesia
PT. Hytera Communications Indonesia started its business back in August 2010 as an office of Hytera Communications Corporation Limited. With seven years’ efforts, Hytera Indonesia office upgraded to PT. Hytera Communications Indonesia. Hytera Communications Indonesia has built its reputation as a leading supplier in Indonesian Professional Mobile Radio (PMR) industry, supporting channel partners and clients in different industries, such as Public Safety and Security, Oil and Gas, Civil Aviation, Railway Transportation, Commercial Business, etc. Hytera can be found throughout the country from INP (Indonesia National Police), Kejaksaan Republik Indonesia (Attorney General of Indonesia), Tanjung Priok Port to Pertamina Oil and Gas plant, Wilmar plantation, and Marriott Hotel, etc.
David Yang, +86 755 2697 2999
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an